Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Prostatic Diseases × apalutamide × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 15 Prostatic Diseases 1 Patient Preference 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castrate-sensitive Prostate Cancer 1 Genital Diseases, Male 1 Adenocarcinoma 1

Interventions

padeliporfin 2 palladium-bacteriopheophorbide 1 enzalutamide 1 darolutamide 1 apalutamide 1 Standard of Care 1 Radiotherapy 1 Prednisone 1 Pluvicto 1 Docetaxel 1 Androgen Antagonists 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

UNICANCER

Phase 3 Recruiting

Genital Diseases, Male, Prostatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡